OCD and Substance Use: Understanding the Dual Diagnosis and How It Is Treated
Around a quarter of people with OCD develop a substance use disorder most often using alcohol, cannabis, or benzodiazepines to dampen distress and the two conditions respond best to integrated treatment by a single team.
Senior Consultant Psychiatrist, Abhasa Rehab and Wellness
- Last Updated: 2026-06-22
- Published: 2026-06-22
- 12 min read
Key Takeaways
- Roughly 25% of people with OCD meet criteria for a substance use disorder at some point in life alcohol most common, followed by cannabis and benzodiazepines.[4]
- The self-medication hypothesis people use substances to dampen OCD distress is well supported by clinical evidence the long-term effect is the opposite of what is sought.
- Integrated treatment of both conditions, by a single team, is the standard. Sequential treatment ("get sober first, then we'll treat the OCD") often fails.
- Withdrawal from alcohol or benzodiazepines requires medical supervision and typically must be stabilised before intensive ERP can begin.
- Cannabis can worsen OCD and anxiety in ways that take weeks to clear after stopping.
- Benzodiazepines, although briefly calming, undermine ERP and create dependence; they are not a treatment for OCD.
People with Obsessive-Compulsive Disorder use substances at higher rates than the general population. Estimates from clinical and community samples suggest that roughly 25% of people with OCD will meet criteria for a substance use disorder at some point in their lives, with alcohol being the most common, followed by cannabis and prescription drugs.
The reasons are not mysterious severe untreated OCD is exhausting, and substances reduce, briefly and unreliably, the anxiety and intrusive thoughts that fill a person’s day.
The cost of that brief relief is high: substances make OCD worse over time, undermine treatment, and create a separate condition that has to be addressed.
This guide explains why OCD and substance use travel together, what the clinical picture looks like in India, why integrated treatment matters, what specific risks each major substance carries for people with OCD, and how dual-diagnosis treatment is delivered.
What does "OCD and substance use" mean clinically?
It refers to the co-occurrence of Obsessive-Compulsive Disorder (ICD-10 F42, DSM-5-TR) and a substance use disorder, most commonly Alcohol Use Disorder (F10), Cannabis Use Disorder (F12), or Sedative/Hypnotic Use Disorder (F13, often involving benzodiazepines).
The two conditions interact, complicate each other, and respond best to integrated treatment delivered by clinicians who can address both.
Who This Guide Is For
This guide is written for:
- Adults with OCD who are using alcohol, cannabis, prescription medications, or other substances to cope with symptoms.
- Family members noticing a loved one’s drinking, cannabis use, or pill use rising alongside their OCD struggle.
- General practitioners and counsellors in India who often see one of the two conditions clearly and need a framework for the other.
- Referring psychiatrists and addiction specialists working with dual-diagnosis presentations.
If you or your loved one feel unsafe, please call iCall (9152987821) or Tele-MANAS (1-800-91-4416). If alcohol or benzodiazepine withdrawal is suspected, please reach a doctor. Abhasa 24/7 Helpline: +91-73736-44444
How Often Do OCD and Substance Use Co-Occur?
QUICK ANSWER
Around 25% of people with OCD will meet criteria for a substance use disorder at some point in their lives. Alcohol is the most common, followed by cannabis and benzodiazepines.[4]
The Indian National Mental Health Survey 2015–16 documented substantial substance use comorbidity across mental disorders, including OCD, with alcohol use disorder being particularly prevalent in male populations.
The figures vary across studies, but the overall pattern is clear. International studies of OCD samples have reported lifetime substance use disorder rates ranging from approximately 20% to 30%, with alcohol use disorder being the most common single substance use disorder.[4]
Onset patterns vary sometimes the OCD precedes the substance use, sometimes the substance use precedes or unmasks the OCD. The two often intensify together over time when neither is treated.
The Indian picture, drawn from the National Mental Health Survey of India 2015–16 conducted by NIMHANS for the Ministry of Health and Family Welfare, documented a current OCD prevalence of approximately 0.8% of adults, with substantial comorbidity across substance use, anxiety, and depressive disorders.
Alcohol use disorder is particularly prevalent in Indian male populations, and many men with untreated OCD develop alcohol-related problems over time.
Why Do People with OCD Use Substances?
QUICK ANSWER
The most common reason clinically and in patient self-report is to dampen the anxiety and intrusive thoughts of OCD. Alcohol blunts anxiety acutely. Cannabis can briefly quiet rumination. Benzodiazepines reduce arousal.
Each provides a short-term dampening that is genuinely felt as relief. The long-term cost is that severe tolerance develops, OCD worsens, and a substance use disorder takes hold alongside the OCD.
The pattern most patients describe is the same. The OCD is loud hours a day of obsessions and compulsions, exhaustion, shame, sleep disruption. They discover, often by accident, that a few drinks in the evening or a cannabis joint quiets the noise for an hour or two. The relief feels real.
Then they start using that quieting effect deliberately. Over weeks and months, the use becomes daily, the doses needed increase, and tolerance builds. Eventually the substance use is its own problem, on top of OCD that has not improved and may have worsened.
Three substances dominate this picture in India
Neither, individually. The standard is integrated treatment in which both conditions are addressed concurrently by a single coordinated team. If alcohol withdrawal is a medical concern, medical detoxification comes first as a stabilisation step.
Increasingly common in younger adults. The acute effect is sometimes calming for a particular individual; for others particularly those vulnerable to anxiety or psychosis the effect is the opposite. Long-term cannabis use is associated with worsening of anxiety and OCD symptoms in many people, and a paradoxical worsening of intrusive thinking.
Benzodiazepines (alprazolam, clonazepam, diazepam, lorazepam): Often started on prescription for “anxiety” and continued without proper psychiatric oversight. The acute calming is real. The long-term effect is dependence, tolerance, and — critically for OCD — the gradual undermining of exposure work. Benzodiazepines are not first-line treatment for OCD and are not a substitute for it.
Less commonly seen but clinically important stimulants (which can dramatically worsen OCD by increasing arousal and attentional fixation), opioids, and over-the-counter medications are used in non-prescribed ways.
How Substance Use Makes OCD Worse
QUICK ANSWER
Substance use makes OCD worse through several mechanisms, disrupting sleep (which amplifies anxiety and intrusive thinking), interfering with the inhibitory learning that ERP requires, creating withdrawal-driven anxiety that mimics or intensifies OCD, and reducing engagement in treatment generally.
Five mechanisms matter clinically:
Alcohol fragments sleep, particularly the second half of the night. Cannabis suppresses REM sleep. Benzodiazepines alter sleep architecture. Poor sleep amplifies anxiety, intrusive thinking, and difficulty disengaging from obsessions the next day.
ERP works by helping the brain learn through real repeated experience that the feared outcome does not happen, even when the obsession is felt at full intensity. Substances that pharmacologically reduce that distress get in the way of that learning.
A person who does an exposure after a drink or a benzodiazepine may feel they got through it, but the underlying fear memory is not updated. Over time, ERP fails to consolidate.
The hours after the substance wears off the “rebound” are marked by elevated anxiety, agitation, and sometimes panic. This rebound anxiety is often experienced by the person as worsening OCD.
The cycle of drinking to calm OCD-feeling-anxiety, then experiencing rebound-anxiety that looks like worsening OCD, then drinking again, is a common trap.
Daily substance use makes attending appointments, doing ERP homework, and engaging with family work harder. Recovery requires showing up; substances reduce showing up.
Chronic alcohol use disrupts the GABA system and contributes to lasting anxiety. Chronic cannabis use is associated with paradoxical worsening of anxiety in vulnerable individuals.
Stimulants directly worsen OCD. The long-term picture is a brain less able to settle into recovery.
Substance-Specific Risks for People with OCD
Alcohol
QUICK ANSWER
Alcohol is the most commonly co-used substance in OCD. Acute use blunts anxiety briefly; chronic use worsens OCD, fragments sleep, and creates dependence.
Withdrawal from heavy alcohol use can be medically dangerous, including seizures and delirium tremens and requires medical supervision. Alcohol also amplifies the suicide risk that exists in OCD with depression.
The clinical picture in alcohol-OCD co-occurrence often involves a person who started using alcohol for OCD-driven anxiety and now drinks daily, with rebound anxiety in the morning, fragmented sleep, and OCD that is louder rather than quieter.
Detoxification under medical supervision is the entry point to integrated treatment. Pharmacotherapy for alcohol use disorder (acamprosate, naltrexone, disulfiram in selected cases) can be combined with the SSRI for OCD.
Cannabis
QUICK ANSWER
Cannabis effects vary widely between individuals. For some, it acutely reduces anxiety; for many with anxiety or OCD vulnerabilities, it acutely or chronically worsens these symptoms. Long-term use is associated with worsening intrusive thinking, paradoxical anxiety, and reduced motivation that interferes with ERP engagement.
Cannabis use disorder typically requires structured psychosocial treatment rather than medication. Stopping cannabis often produces worsening anxiety and sleep disturbance for several weeks; this is withdrawal-related and resolves with time.
But it can be misread as worsening OCD and used to justify resumed use, which is one reason having a clinical team that understands both conditions matters so much.
Benzodiazepines
QUICK ANSWER
Benzodiazepines are not a treatment for OCD. They acutely reduce anxiety but undermine ERP and create dependence. People with OCD who are on long-term benzodiazepines often need a planned, slow taper alongside SSRI titration and ERP work not abrupt discontinuation, which can be dangerous.
Benzodiazepine dependence is one of the more difficult clinical pictures because the medication is often felt as essential. A planned taper, run over weeks to months depending on dose and duration, alongside SSRI introduction and ERP work, is the standard approach. Abrupt discontinuation is dangerous (seizure risk) and should not be attempted without medical supervision.
Stimulants and Other Substances
Stimulant use (cocaine, methamphetamine, prescription stimulants used non-medically) typically worsens OCD acutely and chronically by increasing arousal and attentional fixation.
Opioid use is less common in this clinical picture but creates its own dependence and withdrawal challenges. Over-the-counter medications used in non-prescribed ways, codeine-containing cough preparations, and sedating antihistamines are a sometimes-overlooked part of the picture.
Substance-by-Substance Summary: OCD Interaction and Clinical Priority
| Substance | Effect on OCD symptoms (short-term) | Effect on ERP/treatment | Typical clinical priority |
|---|---|---|---|
|
Substance
Alcohol
|
Effect on OCD symptoms (short-term)
Temporary anxiety reduction
|
Effect on ERP/treatment
Undermines extinction learning rebound anxiety worsens obsessions
|
Typical clinical priority
Medical detox first if dependent SSRI + ERP in parallel
|
|
Substance
Cannabis
|
Effect on OCD symptoms (short-term)
Variable; often increases obsessions over time
|
Effect on ERP/treatment
Reduces ERP-required distress tolerance
|
Typical clinical priority
Cessation 4–6 weeks before intensive ERP
|
|
Substance
Benzodiazepines
|
Effect on OCD symptoms (short-term)
Acute anxiety reduction
|
Effect on ERP/treatment
Blocks inhibitory learning during ERP
|
Typical clinical priority
Planned slow taper with psychiatric oversight
|
|
Substance
Stimulants
|
Effect on OCD symptoms (short-term)
Increases obsessions and compulsions
|
Effect on ERP/treatment
Worsens OCD severity directly
|
Typical clinical priority
Cessation; assess for underlying ADHD if present
|
Why Integrated Treatment Matters
QUICK ANSWER
The historical model “treat the addiction first, then deal with the mental health condition” fails repeatedly in OCD. Untreated OCD drives relapse to substance use. Integrated treatment, in which both conditions are formally diagnosed, both are treatment-planned, and both are addressed concurrently by a single coordinated team, is the standard for dual-diagnosis care.
Sequential treatment fails because it underestimates what drives the substance use. If OCD has been the engine of distress and substance use was the dampening, removing the substance without treating the OCD leaves the engine running.
The person enters early sobriety with the full force of untreated OCD and very few coping resources. Relapse is common.
Integrated treatment looks different in practice:
The psychiatrist, addiction physician, therapist, and family are coordinated. There is one treatment plan with both conditions in it.
The Y-BOCS for OCD and standard substance use measures (CIWA for alcohol withdrawal, AUDIT for screening) are used together.
If alcohol or benzodiazepine dependence is established, medical detox under appropriate supervision is the entry point. Intensive ERP starts after stabilisation.
Medications like Naltrexone or acamprosate for alcohol use disorder run alongside the SSRI.
Therapy that integrates ERP for OCD with relapse-prevention work for the substance use.
Addresses both the family accommodation of OCD and the family dynamics around the substance use.
How Integrated Dual-Diagnosis Treatment Is Delivered, Step by Step
Both conditions are assessed concurrently by a coordinated team. Both diagnoses go into a single shared treatment plan from day one.
If alcohol or benzodiazepine dependence creates withdrawal risk, medical detoxification under clinical supervision comes first.
An SSRI is initiated and titrated toward the OCD-effective dose range. Substance use is reduced or stopped in close parallel.
ERP is conducted in a substance-free environment so that inhibitory learning can occur.
Discharge planning addresses both OCD maintenance (continued ERP, SSRI adherence) and substance-use relapse prevention.
When Residential Care Is the Right Setting
QUICK ANSWER
Residential dual-diagnosis care is considered when home-based detoxification and outpatient treatment are not safe or sufficient when withdrawal risk is high, when substance use has become daily and severe, when prior outpatient attempts have not held, when OCD impairment is severe, or when the home environment is not conducive to early recovery.
A higher level of care is considered when one or more of the following applies:
- Alcohol or benzodiazepine withdrawal risk that needs medical monitoring.
- Daily heavy substance use with multiple prior failed quit attempts.
- OCD impairment so severe that outpatient ERP has not been able to take hold.
- Co-occurring severe depression with suicide risk.
- Home environment that is reinforcing either condition.
- Need for intensive, daily integrated treatment that outpatient sessions cannot deliver.
How Abhasa Approaches OCD with Substance Use
At Abhasa Rehab and Wellness, dual-diagnosis presentations, including OCD with alcohol or substance use, are a core part of what our integrated team treats.
- Joint psychiatric and addiction medicine assessment at intake.
- Medical detoxification under appropriate supervision when withdrawal risk is present.
- Integrated medication planning combining SSRIs with appropriate pharmacotherapy for substance use.
- Therapy delivered by cross-trained clinicians experienced in both ERP and relapse-prevention work.
- Family work that addresses relationship dynamics without blame.
- Residential structure for safety and early recovery stabilization.
Not sure if this applies to your situation?
Call +91-73736-44444 / info@abhasa.in / WhatsApp also available. contact us online via the Abhasa website.
Frequently Asked Questions
Neither, individually. The standard is integrated treatment in which both conditions are addressed concurrently by a single coordinated team. If alcohol withdrawal is a medical concern, medical detoxification comes first as a stabilisation step.
It can be. Alcohol withdrawal in someone who has been drinking heavily and daily for weeks or months can cause seizures, delirium tremens, and other dangerous medical complications. Please involve a doctor for medical detoxification.
Long-term benzodiazepines are not first-line treatment for OCD and are likely undermining ERP. The right answer is not abrupt cessation that can be dangerous but a planned taper agreed with a psychiatrist.
SSRIs can be initiated alongside reduction or cessation of drinking, but their effect on OCD is less likely to be properly assessed if heavy drinking is ongoing. Sleep disruption and rebound anxiety interfere with the medication’s effectiveness.
ERP works less well in active substance use. Cannabis can reduce the distress that ERP relies on for inhibitory learning to occur. Most clinicians aim for cessation or substantial reduction before intensive ERP work.
Keep contact warm and judgement-free, avoid lecturing, focus on specific concrete next steps (like a single appointment with a clinician), look after your own mental health, and consider speaking to a psychiatrist about how to bring your loved one in.
More questions?
More questions? Speak with our team confidentially. Call +91-73736-44444 or visit Abhasa OCD.
Closing — A Realistic Picture
OCD and substance use disorders co-occur often, interact in damaging ways, and respond best to integrated treatment delivered by a single coordinated team. Sequential approaches frequently fail because untreated OCD drives relapse.
The standard of care is concurrent diagnosis, medical stabilisation where needed, SSRIs for OCD plus appropriate addiction pharmacotherapy where indicated, ERP integrated with relapse-prevention work, and family work that addresses both pictures honestly.
Continue Your Learning
If you would like to explore further, our umbrella guide on Obsessive-Compulsive Disorder gives a broader picture of how OCD shows up across all subtypes.
Our OCD Treatment Centre page covers what residential and outpatient programmes look like in practice. And if you are still working out which subtype fits your experience, the pillar on Types of OCD walks through all six side by side.
References
[1] Koran LM et al. — APA Practice Guideline for OCD (AJP, 2007)
This paper was published in The American Journal of Psychiatry, Vol. 164, No. 7 Suppl, July 2007, pp. 5–53, by Lorrin M. Koran and colleagues on behalf of the American Psychiatric Association.
https://pubmed.ncbi.nlm.nih.gov/17849776/
[2] Pallanti S et al. — OCD Comorbidity (Frontiers in Psychiatry, 2011)
This paper (PMID: 22203806; PMCID: PMC3243905) was published in Frontiers in Psychiatry, 2011 Dec 21;2:70. DOI: 10.3389/fpsyt.2011.00070. It is a free PMC article.
https://pubmed.ncbi.nlm.nih.gov/22203806/
[3] Gururaj G et al. — National Mental Health Survey of India 2015–16 (NIMHANS, 2016)
This is a government/institutional report, not a journal article — it is not indexed on PubMed. The full title is National Mental Health Survey of India, 2015–16: Prevalence, Patterns and Outcomes, NIMHANS Publication No. 129, 2016, published by the National Institute of Mental Health and Neuro Sciences, Bengaluru.
https://www.mohfw.gov.in/sites/default/files/National%20Mental%20Health%20Survey,%202015-16%20-%20Prevalence,%20Pattern%20&%20Outcomes_0.pdf
[4] Mancebo MC et al. — Substance Use Disorders in OCD (J Anxiety Disorders, 2009)
This paper (PMID: 18954963; PMCID: PMC2705178; DOI: 10.1016/j.janxdis.2008.08.008) was published in Journal of Anxiety Disorders, 2009 May;23(4):429–35. It is a free PMC article.
https://pubmed.ncbi.nlm.nih.gov/18954963/
[5] Brady KT et al. — Comorbidity of Psychiatric Disorders and PTSD (J Clin Psychiatry, 2000)
This paper was published in Journal of Clinical Psychiatry, 2000;61 Suppl 7:22–32 (PMID: 10795606). It is a review article with no free PMC full text.
https://pubmed.ncbi.nlm.nih.gov/10795606/
[6] Goodman WK et al. — Y-BOCS Development & Reliability (Arch Gen Psychiatry, 1989)
This paper was published in Archives of General Psychiatry, 1989 Nov;46(11):1006–11. DOI: 10.1001/archpsyc.1989.01810110048007. PMID: 2684084.
https://pubmed.ncbi.nlm.nih.gov/2684084/
- Reviewed by
- Senior Consultant Psychiatrist
- Abhasa Rehab and Wellness
Medical Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional for personalised medical guidance. If you or someone you know is in crisis, please contact emergency services (112) or one of the helplines listed above. If alcohol or benzodiazepine withdrawal is suspected, do not stop abruptly — please reach a doctor.
A reminder. If you are in crisis, or if alcohol or benzodiazepine withdrawal is suspected, please reach a doctor or call:
Crisis lines (24/7 unless noted):
- iCall (TISS): 9152987821 (Mon–Sat, 10 am–8 pm)
- Vandrevala Foundation: 1860-2662-345 (24/7)
- AASRA: 9820466627 (24/7)
- Tele-MANAS (Govt of India): 1-800-91-4416 (24/7)
Abhasa 24/7 Helpline: +91-73736-44444.
If withdrawal from alcohol or benzodiazepines is suspected, do not stop abruptly without medical supervision. Sudden cessation can be dangerous. Please reach a doctor or hospital.